# Lansoprazole

## Takepron Intravenous 30mg

| TAH Drug Code      | [ITAK](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITAK)                                                                                                                                                |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | As an alternative to oral therapy when oral intake is not appropriate for GERD in patients with esophagitis &/or severe symptoms of reflux & for healing of gastric ulcers associated with NSAID therapy.           |
| Dosing             | 30 mg IV once or twice daily infusion over 30 minutes.                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                       |
| Contraindications  | Hypersensitivity to Lansoprazole.                                                                                                                                                                                   |
| Adverse Effects    | Headache, abdominal pain, diarrhea, flatulence, nausea/vomiting, constipation. Abnormal hepatic function tests, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum ALT, increased serum AST. |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data â€“ Potential Toxicity(Mother)                                                                                                                                                                |

## Takepron OD 30mg

| TAH Drug Code      | [OTAK](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OTAK)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of gastric ulcers, duodenal ulcers, gastroesophageal reflux disease - erosive esophagitis, symptomatic treatment of gastroesophageal reflux disease. Zollinger-Ellison syndrome, combined with antibiotics for Helicobacter pylori-related peptic ulcers, and treatment of stomach ulcers caused by NSAIDs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Take Takepron 1 hour before meals, do not crush or chew. Avoid use in children aged 1-17 for over 12 weeks. Adult: - Ulcer of duodenum, short-term treatment: 15 mg PO QD up to 4 weeks. - Gastric ulcer, short-term treatment of active ulcer: 30 mg PO QD up to 8 weeks. - Gastric ulcer, treatment of NSAID-associated gastropathy: 30 mg PO QD for 8 weeks. - Gastroesophageal reflux disease (GERD): 15 mg PO QD up to 8 weeks. - Erosive esophagitis, short-term treatment: 30 mg PO QD for 8 weeks. - Zollinger-Ellison syndrome: 60 mg PO QD up to 90 mg BID.- Pediatric: - Erosive esophagitis: (1-11 years, <=30 kg or less) 15 mg PO QD for 8-12 weeks. (1-11 years, >30 kg) 30 mg PO QD for 8-12 weeks. (12-17 years) 30 mg PO QD for up to 8 weeks. - Gastroesophageal reflux disease: (1-11 years, less than or equal-30 kg) 15 mg PO QD for up to 12 weeks. (1-11 years, greater than 30 kg) 30 mg PO QD for up to 12 weeks. (12-17 years) 15 mg PO QD for up to 8 weeks. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Known hypersensitivity including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria to any component of the product. Concomitant use with rilpivirine-containing products.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common: Abdominal pain (Up to 5%), Constipation (1-5%), Diarrhea (Up to 7.4%), Nausea (1.3-3%), Headache (1%) Serious: Cutaneous lupus erythematosus, Erythema multiforme, Acute generalized exanthematous pustulosis, Acute generalized exanthematous pustulosis, Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), Hypomagnesemia, Clostridium difficile diarrhea, Fundic gland polyposis of stomach, Pancreatitis, Anaphylaxis, Drug reaction with eosinophilia and systemic symptoms (DRESS), Fracture of bone, Rhabdomyolysis, Acute tubulointerstitial nephritis                                                                                                                                                                                                                                                                                                                                                                                                   |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

